Terns Pharmaceuticals (TERN) Gains from Investment Securities (2021 - 2023)
Historic Gains from Investment Securities for Terns Pharmaceuticals (TERN) over the last 3 years, with Q3 2023 value amounting to $65000.0.
- Terns Pharmaceuticals' Gains from Investment Securities fell 2613.64% to $65000.0 in Q3 2023 from the same period last year, while for Dec 2023 it was $65000.0, marking a year-over-year decrease of 9592.48%. This contributed to the annual value of $1.3 million for FY2024, which is 190307.69% up from last year.
- Terns Pharmaceuticals' Gains from Investment Securities amounted to $65000.0 in Q3 2023, which was down 2613.64% from -$6000.0 recorded in Q4 2022.
- In the past 5 years, Terns Pharmaceuticals' Gains from Investment Securities ranged from a high of $3.6 million in Q3 2021 and a low of -$6000.0 during Q4 2022
- Its 3-year average for Gains from Investment Securities is $1.1 million, with a median of $238000.0 in 2021.
- As far as peak fluctuations go, Terns Pharmaceuticals' Gains from Investment Securities tumbled by 10252.1% in 2022, and later plummeted by 2613.64% in 2023.
- Quarter analysis of 3 years shows Terns Pharmaceuticals' Gains from Investment Securities stood at $238000.0 in 2021, then crashed by 102.52% to -$6000.0 in 2022, then surged by 1183.33% to $65000.0 in 2023.
- Its Gains from Investment Securities stands at $65000.0 for Q3 2023, versus -$6000.0 for Q4 2022 and $88000.0 for Q3 2022.